Disease
Acute Myeloid Leukemia
An aggressive hematologic malignancy of myeloid progenitor cells, primarily affecting older adults and treated with molecularly stratified induction, consolidation, maintenance, and relapse regimens.
Coverage in progress. AssetMemo has not yet run its full census for Relapsed/Refractory Acute Myeloid Leukemia, so the assets listed for it are not complete.
Combined attributable cost
$4.3B+
Drug spend
Not yet sourced
Sum of 2 indications below.